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Background: It has been reported that direct activation of the cannabinoid CB1 receptor in epidermal growth
factor (EGR)-stimulated PC-3 prostate cancer cells results in an anti-proliferative effect accompanied by a
down-regulation of EGF receptors (EGFR). In the present study, we investigated whether similar effects are
seen following inhibition of the endocannabinoid hydrolytic enzyme monoacylglycerol lipase (MGL).
Results: CB1 receptor expression levels were found to differ greatly between two experimental series
conducted using PC-3 cells. The monoacylglycerol lipase inhibitor JZL184 increased levels of 2-arachidonoylglycerol in
the PC-3 cells without producing changes in the levels of anandamide and related N-acylethanolamines. In the first
series of experiments, JZL184 produced a small mitogenic effect for cells that had not been treated with EGF, whereas
an anti-proliferative effect was seen for EGF-treated cells. An anti-proliferative effect for the EGF-treated cells was also
seen with the CB receptor agonist CP55,940. In the second batch of cells, there was an interaction between JZL184
and CB1 receptor expression densities in linear regression analyses with EGFR expression as the dependent variable.
Conclusions: Inhibition of MGL by JZL184 can affect EGFR expression. However, the use in our hands of PC-3 cells as
a model to investigate the therapeutic potential of MGL inhibitors and related compounds is compromised by their
variability of CB1 receptor expression.
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It is now well established that ligands activating canna-
binoid (CB) receptors, can affect the viability of a variety
of different cancer cells lines [1]. With respect to pros-
tate cancer (Pca) cells, Nithipatikom et al. [2] reported
that compounds reducing the synthesis of the endocan-
nabinoid ligand 2-arachidonoylglycerol (2-AG) increased
the invasivity of the cells in vitro, whereas the reverse
was seen when the metabolism of this endocannabinoid
was blocked. A subsequent study reported that a select-
ive blockade of the primary 2-AG metabolising enzyme
monoacylglycerol lipase (MGL), either by use of the* Correspondence: cf@pharm.umu.se
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down of the enzyme, affected cell survival and invasion
in vitro and reduced tumour growth in a xenograft
model [3]. This effect was due in part to activation of
CB1 receptors by the increased 2-AG concentration, and
in part to blockade of the production of long chain fatty
acids by the MGL-catalysed hydrolysis of the corre-
sponding monoacylglycerols [3]. Fatty acid amide hydro-
lase (FAAH), the enzyme responsible for hydrolysis of
the other main endocannabinoid anandamide (AEA), is
also overexpressed in Pca [4,5] and transfection of cul-
tured Pca cells with this enzyme increases their invasiv-
ity [4].
Taken together, the studies described above suggest
that the endocannabinoid system can act as a local regu-
latory mechanism to keep Pca cells in check and thatl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 CB1 receptor expression in PC-3 cells: effect of EGF.
Cells were incubated for 3 weeks in the absence or presence of EGF
(10 ng/ml). The x-axis shows the CB1 receptor expression, normalised
to β-actin for the individual samples, colour coded on the basis of
their experimental series. The y-axis shows the CB1 receptor
expression, normalised to β-actin, in the presence of EGF as a ratio of
the expression from another well in the same culture plate cultured
in the absence of EGF. The dotted line is at a value of unity, i.e. no
stimulation of CB1 receptor expression by EGF. The Spearman
rho values are shown in the Panel.
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by which activation of CB receptors affect Pca cell survival
are a matter of current research [1], but one important
route is via a down-regulation of the receptors for epider-
mal growth factor (EGF) [6]. These receptors (EGFR)
are involved in the regulation of cell growth and sur-
vival, and overexpression of their phosphorylated (active)
form is associated with a poor disease-specific survival [7].
Mimeault and colleagues [6] showed that treatment of
Pca cells, including PC-3 androgen-independent Pca cells
with AEA reduced the expression of EGFR in a manner
blocked by the CB1 receptor antagonist rimonabant,
and this was accompanied by a marked inhibition of
the maximal EGF-induced proliferation of the cells. These
authors, however, did not investigate whether increasing
endogenous levels of endocannabinoids by blockade
of their hydrolysis produced the same results. In Pca
tumours, CB1 receptor and phosphorylated EGFR immu-
noreactive scores are positively correlated and provide
additive prognostic information with respect to disease-
specific survival [8].
The finding that CB1 receptor activation mitigates the
effects of EGFR in Pca cells [6] is potentially important
in therapeutic terms. In the present study, we have in-
vestigated the effects of inhibition of 2-AG hydrolysis by
JZL184 upon the proliferation and EGFR expression of
PC-3 cells.
Results
Inter-experimental variation in CB1 receptor expression in
PC-3 cells
Two series of experiments were undertaken using PC-3
cells. The cells were cultured for a total of three weeks
without medium change in the absence or presence of
EGF (10 ng/ml) (for details, see Methods section). In the
first series, a robust expression of CB1 receptors was
seen. However, in the second series of experiments con-
ducted about half a year later with a new batch of cells
but using the same methodology, the levels were very
much lower (Figure 1). The cells also behaved differently
in their responsiveness to long-term treatment with EGF.
For the first experimental series, the EGF treatment in-
creased the observed CB1 receptor expression by ~5 fold
(median value), whereas no such increase was seen for the
second series (Figure 1).
The influence of EGF upon the expression of sensitivity of
PC-3 cells to CP55,940 and JZL184
As part of the first series of experiments with EGF, the
cells were treated for the last week with either vehicle or
JZL184 (1 μM). The JZL184 treatment produced the ex-
pected increase in 2-AG levels without affecting either
AEA or related N-acylethanolamide levels (Figure 2A).
The effect of this compound upon the cell proliferationis shown in Figure 2B. A two-way ANOVA matching for
JZL184 indicated a significant interaction JZL184 × EGF
(F1,10 = 84, P < 0.0001), due to a stimulation of cell pro-
liferation by the compound for control cells and an in-
hibition for the EGF-treated cells.
The CB agonist CP55,940 (100 nM) was also investi-
gated in the first series PC-3 cells, although in this case
the cells were both counted by FACS and sorted on the
basis of their pAkt and pErk immunoreactivities using
the FlowCellectTM PI3K/MAPK Dual Pathway Activa-
tion and Cancer Marker Detection kit (Merck Millipore,
Billerica, MA, USA). An example of the readout for EGF-
treated cells is shown in Figure 3. As with JZL184, a sig-
nificant interaction EGF: CP55,940 was found with the
number of cells as endpoint (Figure 2C; two-way ANOVA
matching for CP55,940: F1,8 (EGF × CP55,940) = 23.65,
p < 0.005). The EGF treatment also increased the number
of cells in the lower right FACS quadrant following cell
sorting (i.e. high pAkt, low pErk expression) and this was
also reduced by the CP55,940 treatment (Figure 4). Initial
experiments indicated that the inhibition of cell prolif-
eration in the EGF-treated cells by 100 nM CP55,940
was not blocked by the CB1 receptor inverse agonist
AM251 (100 nM data not shown), suggesting that the ef-
fect of CP55,940 at this concentration may be mediated
by a non-CB1 receptor pathway. Higher concentrations
of AM251 were not tested, since they produce rapid anti-
proliferative effects in PC-3 cells with low levels of
CB1 receptor expression [9]. AM251 (admittedly at higher
Figure 2 Effects of JZL184 and CP55,940 upon PC-3 cell proliferation. Cells were incubated for 3 weeks in the absence or presence of EGF
(10 ng/ml). Cells in 6 well plates were treated for three weeks without medium change in the absence or presence of 10 ng/ml of EGF. A and B:
After two of the three weeks, either vehicle or JZL184 (1 μM) was added to the wells and the incubation was continued for a week without
change of medium. In A, levels of 2-AG and N-acylethanolamines are shown. The data, taken for both PC-3 experimental series, show the total
levels of the lipids in the cell extract expressed relative to the corresponding value for the extracts taken from wells containing control cells from
the same plate. The bars show median values. Abbreviations: 2-AG, 2-arachidonoylglycerol; AEA, anandamide; PEA, palmitoylethanolamide; OEA,
oleoylethanolamide; SEA, stearoylethanolamide. In B the data are from the first experimental series, and values are means ± s.e.m., n = 6. **P <
0.01, ***P < 0.001, Šídák’s multiple comparison test vs. the corresponding vehicle control following a significant interaction term in the two-way
ANOVA matching for JZL184. In C (first experimental series), the same experimental protocol was followed, but using 100 nM CP55,940 (“CP”).
In C, data is given as means ± s.e.m., n = 7 (EGF-treated) or n = 3 (no EGF). **P < 0.01, NSnot significant, Šídák’s multiple comparison test vs. the
corresponding vehicle control following a significant interaction term in the two-way ANOVA matching for CP55,940.
Figure 3 Cell signalling by PC3 cells. The figure shows a FACS run
for cells treated for a total of three weeks with 10 ng/ml EGF without
medium change.
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and its ligands in PANC-1 pancreatic cancer cells, which
lack CB1 receptors [10], so effects (or the lack of them) at
higher concentrations of the compound would be very dif-
ficult to interpret.
The influence of JZL184 upon the expression of CB1 and
EGF receptors
For the low CB1 receptor-expressing PC-3 cells (i.e. the
second experimental series), the effects of EGF and
JZL184 upon EGFR expression were investigated (Figure 5)
and linear regression analyses were performed. For these
analyses, the data for CB1 receptor and EGFR expression
were logged since residual plots of the regressions using
untransformed data were not considered acceptable for
parametric analysis (not shown). Using the logged data
and with EGFR/β-actin as the dependent variable, the un-
standardized coefficients obtained were: EGF, 0.019 ±
0.057, P > 0.7; JZL184, -0.12 ± 0.056, P < 0.05; CB1R, 0.31 ±
0.24, P > 0.2; interaction term EGF × CB1R, 0.078 ± 0.26,
P > 0.7; interaction term JZL184 × CB1R, -0.72 ± 0.31,
P < 0.05; interaction term EGF × JZL184 × CB1R, 0.46 ±
Figure 4 Effect of EGR and CP55,940 upon the intracellular signalling of human PC-3 prostate cancer cells. Cells were treated for two
weeks without medium change in the absence or presence of 10 ng/ml EGF. Vehicle or 100 nM CP55,940 (“CP”) was then added and the cells
were incubated for a further week. Cut-offs (shown by the red lines in Figure 3) were used to define the number and hence % of cells in the four
quadrants. (means ± s.e.m., n = 7). P values given in the figures refer to one-way repeated measure ANOVAs not assuming sphericity. **P < 0.01,
Tukey’s multiple comparison test following significant ANOVA.
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and the ANOVA for the regression was F6,35 = 2.89, P <
0.05. Inclusion of the interaction terms in the model in-
creased the adjusted r2 value from 0.092 to 0.244.
The finding of a significant interaction CB1R × JZL184
allows separate statistical analysis of the untransformed
data in the absence or presence of this compound. In the
absence of JZL184, a significant correlation between the
CB1 receptor expression and the EGFR was seen, but this
was lost in the presence of JZL184 (Figure 5).Discussion and conclusions
The present study was designed to determine whether in-
creasing endogenous 2-AG via MGL inhibition affects the
proliferation of EGF-stimulated PC-3 cells secondary to a
down-regulation of EGFR expression, consistent with the
work of Mimeault and colleagues [6] who used exogen-
ously added AEA as a direct-acting CB1 receptor agonist.
The protocol we used, whereby cells are incubated for
three weeks with EGF without medium change sounds
somewhat draconian, but in many ways better represents
Figure 5 Effects of EGF and JZL184 upon CB1 receptor and EGFR expression in PC3 cells. Cells from the second experimental series were
incubated with EGF and JZL184 as described in the legend to Figure 2. The EGFR mRNA is shown as a function of the CB1 receptor mRNA, both
normalised to β-actin, for the second series cells, each data point being for a given well. Shown in each Panel are the Spearman rho values.
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environment) than standard culturing conditions [11].
The predominant finding of the study is that the ex-
pression of CB1 receptors in the PC-3 cells varied con-
siderably between the two experimental series. This is
not the first time a variation in cell phenotypes has been
reported by any means (see [12] and references cited
therein), although the only report to our knowledge with
respect to the cannabinoid system is from 2003, where
we reported that the sensitivity of C6 glioma cells to the
anti-proliferative effects of AEA and the 1-regioisomer
of 2-AG varied considerably between experiments [13].
This was not due to a solubility issue of these ligands,
since the water-soluble analogue phospho-AEA showed
the same inter-experimental variation. In contrast, the
AEA analogue methanandamide, which inhibited the pro-
liferation in a CB1 receptor-independent manner, showed
no inter-experimental variability [13]. Variabilities like
these and cell responses to other treatments [12] are likely
to be under-reported in the literature, but are important
with respect to the robustness of the model in question.
The reasons why CB1 receptor expression was so differ-
ent for the two batches of PC-3 cells is unclear, but could
be related, for example, to effects on gene transcription in-
duced during the thawing and subsequent culture of the
cells. An alternative speculation is that variations in the
composition of the foetal serum albumin can affect gene
expression. Levels of 2-AG and AEA vary dramatically in
different commercial foetal bovine sera batches, and in
some cases, this is sufficient to affect cell phenotypes
[14]. Whatever the explanation, such a variation can in
itself provide a plausible explanation for the differences in
CB1 receptor-mediated anti-proliferative effects of canna-
binoids if it is argued that a threshold level of expression
is required for CB1 receptor-mediated anti-proliferative
effects to occur. Thus, for example, in DU-145 cells,
which under the conditions used expressed sufficient CB1receptors to be measurable in radioligand binding experi-
ments, AEA inhibited prolactin-stimulated cell prolifera-
tion in a rimonabant-sensitive manner [15]. In contrast, in
PC-3 cells with a low expression of CB1 receptors under
the conditions used, CP55,940 had no effect upon cell
proliferation after incubation for up to 6 days [9]. A recent
finding from our laboratory that transfection of rat AT1
prostate cancer cells with a murine CB1 receptor changes
the phenotype from one which responds to nanomolar
concentrations of CP55,940 with an increased cell prolifera-
tion to one which responds with a reduced cell proliferation
[16] would support this conclusion. However, this may be
an oversimplification since CB1 receptor-independent ef-
fects of Δ9-tetrahydrocannabinol have been reported in
PC-3 cells expressing these receptors [17].
Although the variation seen here is per se a complicating
factor, some conclusions can be made for the data with
the MGL inhibitor JZL184. In the first batch of cells, there
is a significant interaction JZL184 × EGF that is also seen
for CP55,940 × EGF. At the same time, the EGF treatment
increases the expression at the mRNA level of CB1 recep-
tors. The simplest explanation of the data are that two
processes are occurring: with respect to EGF, the increase
in CB1 receptor expression changes the phenotype of the
cells in the same way as described above for the trans-
fected AT-1 cells. Modest mitogenic effects of low (nano-
molar) concentrations of Δ9-tetrahydrocannabinol have
been reported for PC-3 cells secondary to activation of the
phosphoinositide 3-kinase/protein kinase B pathway [18]
and a similar process may be occurring here. At the higher
CB1 receptor expression levels following EGF treatment,
JZL184 and CP55,940 are anti-proliferative, suggesting
that the cellular pathways involved in these actions
(including down-regulation of EGFR, [1,6]) predominate.
Evidence in support of this was found with the second
batch of cells, despite their low CB1 receptor expression.
There was a significant interaction between CB1R × JZL184
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the dependent variable, whereas the influence of the EGF
treatment was not significant. Analysis of the data suggest
that at these low levels of CB1 receptor expression, the as-
sociation of CB1 and EGFR is lost in the presence of the
MGL inhibitor. This is consistent with the hypothesis that
the MGL inhibitor reduces EGFR expression even at low
levels of CB1 receptor expression.
In conclusion, the data presented here suggest that in-
hibition of MGL by JZL184 can affect EGFR expression,
consistent with the data using AEA to stimulate CB1 re-
ceptors [6]. However, the use in our hands of PC-3 cells
as a model to investigate the therapeutic potential of
MGL inhibitors and related compounds is compromised
by their variability of CB1 receptor expression.
Methods
Cell culture and treatments
Human PC-3 prostate cancer cells (passage numbers 3-
12 for the experiments reported here) were obtained
from DSMZ (Braunschweig, Germany) and cultured in
Hams F-10, 2mM L-glutamine, 10% foetal bovine serum
and penicillin + streptomycin. Cells (2.5 × 105) were added
to 6 well-plates and cultured overnight. The next day,
either medium or EGF (final concentration 10 ng/ml)
was added, and the cells were cultured for two weeks
without change of media. Test compounds (CP55,940
or JZL184 (4-nitrophenyl-4-(dibenzo[d] [1,3] dioxol-5-yl
(hydroxy)methyl)piperidine-1-carboxylate, Cayman Chemical
Co., Ann Arbor, MI, USA)) were then added, without
change of media, and the cells were cultured for a third
week. Cells were then harvested and sorted by FACS
on the basis of their pAkt and pErk immunoreactivities
using the FlowCellectTM PI3K/MAPK Dual Pathway
Activation and Cancer Marker Detection kit (Merck
Millipore, Billerica, MA, USA).
RNA extraction, reverse transcription, and qPCR
Cells that were treated with or without EGF and/or
JZL184 as described above without medium change were
harvested and total RNA was extracted using the miRNeasy
Kit (Qiagen, Hilden, Germany) according to the instruc-
tions by the manufacturer. The RNA was eluted in 30 μl of
RNAse/DNAse-free water and stored at -80°C. The RNA
was quantified using a Nanodrop instrument (Thermo
Scientific, Wilmington, DE, USA), and cDNA was synthe-
sized from 2 μg of total RNA in 20μl reactions using a
cDNA synthesis kit with recombinant moloney murine
leukemia virus (rMoMuLV) reverse transcriptase, RNAse
inhibitor (1.0 U/μl) and random primers (High capacity
cDNA reverse transcription kit; Applied Biosystems,
Foster City, CA, USA) according to the instructions by the
manufacturer. The mRNA levels for human CB1 (CNR1;
NM_016083), EGFR (NM_005228) and the reference geneβ-actin (ACTB; NM_001101) were analysed by quantita-
tive real-time PCR (qPCR) using an ABI PRISM® 7900HT
Sequence Detection System (Applied Biosystems, Foster
City, CA, USA). The qPCR analyses were performed using
TaqMan Universal PCR Master Mix and TaqMan gene
expression assays including 5′ FAM dye labelled probes
(Applied Biosystems, Foster City, CA, USA) for CNR1
(Assay Hs01038522_s1), EGFR (Assay Hs01076078_m1),
and ACΤΒ (Assay Hs00357333_g1). The sample volume
was 10 μl per well (384 well format) and the qPCR run-
ning protocol as follows: Initial steps at 50°C for 2 min
and 95°C for 10 min, followed by 40 cycles of denaturation
at 95°C for 15 sec and annealing/extension at 60°C for 1
min. No amplification was detected in control samples
where cDNA template was omitted (data not shown). The
relative expression of CB1 and EGFR was normalized with
β-actin used as reference gene according to the ΔΔCq
method.
Measurement of 2-AG, AEA and related N-acylethanolamines
in cell extracts
The lipids were extracted as described by Bradshaw et al.
[19]. Briefly, after removal of medium, the cells were
washed twice with phosphate-buffered saline after which
methanol (2 ml) was added. The mixture was scraped
using a rubber policeman and the extract pipetted into
Falcon tubes. An additional 1 ml of methanol was added
to the wells, the wells scraped and the mixture was pipet-
ted into the same tubes. These were then centrifuged at
2000 × g to sediment cell debris, and the methanol phase
collected. Water was added to give a final methanol con-
centration of 30% (v/v). 2-AG, AEA and related lipids in
the extracts were analysed as described elsewhere [20].
Briefly, the cell extracts spiked with internal standard
(AEA-d8, 2-AG-d8 and OEA-d4) were subjected to solid
phase extraction (SPE) on 200 mg Waters Oasis HLB car-
tridges (Milford, MA, USA). After evaporation of the SPE
elutions using a MiniVac system (Farmingdale, NY, USA),
the analytes were reconstituted in 100 μL of metha-
nol. Ten μL of recovery standard (DHEA-d4) was added
and ultra performance liquid chromatography coupled
with electrospray ionization tandem mass spectrometry
(UPLC-ESI-MS/MS) analysis was performed immediately.
A Waters Acquity Ultra Performance (Milford, MA, USA)
equipped with a 2.1 mm× 150 mm Waters BEH C18 col-
umn with a 2.5 μm particle size was used for UPLC with
the following conditions: the autosampler was kept at
10°C, mobile phase A was water, mobile phase B was
methanol with 10 mM ammonium acetate. Gradient elu-
tion was performed at a flow rate of 0.4 mL/min. The col-
umn was connected to a Waters triple quadrupole MS
(Micromass Quattro Ultima) equipped with an ESI source
operating in positive multiple reaction monitoring (MRM)
mode. The optimized conditions and the MRM transitions,
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[20]. MassLynx software was used to quantify the peaks
according to the stable isotope dilution method.
Statistics
Two statistical software programmes were used. ANOVA
and Spearman’s correlation coefficients were determined
using the statistical package built into the GraphPad Prism
computer programme for the Macintosh (GraphPad Software
Inc., San Diego, CA, USA). The linear regression analyses
were undertaken using the IBS SPSS Statistics package,
version 22.
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